The dissociation constants for binding to ribosomes from Escherichia coli and concentrations at which 509, inhibition of ['4C]erythromycin binding to ribosomes occurred were determined for 45 erythromycin analogues. These values were correlated with their antibacterial activities against Bacillus subtilis. Compounds which bound to ribosomes best showed the greatest activities; those which were poorly bound to ribosomes showed little or no antibacterial activity. The ribosomal binding assays therefore reflected the general antibacterial potential of the erythromycin analogues.
We recently studied the binding of [ 14C ]erythromycin to ribosomes from Escherichia coli. In addition, we also determined the association constants for the binding of various erythromycin analogues to ribosomes. Since erythromycin is an effective antibiotic because of its inhibition of protein synthesis through binding to the large subunit of bacterial ribosomes (3, 4, 7) , it was therefore of interest to determine if the in vitro activity of the analogues was related to the association constants we determined in cell-free extracts. In this communication, we report the relative activity of the erythromycin analogues in cell-free extracts compared with their activity on intact bacteria. (6) . As can be seen from the data, erythromycin and all analogues which bind to ribosomes with a dissociation constant of about 60 nM or less are relatively effective antibacterial agents. Their antibacterial activity ranges from 10 to 100% that of erythromycin A. The concentration for 50% inhibition of erythromycin A binding to ribosomes ranged from about 1 to 7.9,M.
MATERIALS AND METHODS

Binding
In the second group of erythromycin analogues, the concentration at which 50% inhibition of [14C]erythromycin binding to ribosomes occurred ranged from 11 to 79.4 MM. The relative antibacterial activity for this group ranged from 1 to 10% that of erythromycin A. The dissociation constants in this group range from about 70 to 1,000 nM.
In the third group, which consisted of erythromycin analogues which were inactive as antibacterial agents in vitro, the <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1  <1 a These compounds were tested against Sarcina lutea rather than B. subtilis. Antibacterial activities of many of the active compounds were tested against both B. subtilis and S. lutea with essential agreement in the values. Where antibacterial activity was less than 1% that of erythromycin A, or where no antibacterial activity was detected, is indicated by <1% in the table.
Previously, Mao (1) and Mao and Putterman (2), as well as Wilhelm et al. (8) , examined the effect of erythromycin analogues or other macrolides on erythromycin binding to ribosomes. this cell-free assay correlated with their antibacterial activity. All compounds in the first group had a relative activity greater than 10%. Compounds in the second group had an activity between 1 and 10% that of erythromycin A. Compounds in the third group were inactive. Thus, the correspondence between the ability of these agents to displace ['4C]erythromycin from ribosomes and their antibacterial activity was quite good.
Since antibacterial activity depends not only on the binding of the analogue to ribosomes but also on its ability to enter and function intact in these cells, differences may be expected for these reasons. In fact, where differences arise, it may be possible to delineate the factors which influence cellular permeability, modification, and other significant parameters. For example, compounds 37 and 44 have approximately equal dissociation constants. Nevertheless, compound 44 is about five times as active as compound 37, based on their antibacterial activity. These results suggest that compound 44 may be transported into the cell better than 37, or that compound 37 undergoes some modification or degradation to an inactive derivative. Further studies are necessary to distinguish between these alternatives. Thus, knowledge of both the in vitro antibacterial activity and the binding to ribosomes of each erythromycin analogue should help elucidate the significant parameters contributing to functional antibacterial agents.
